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Abstract
Background: Numerous pathologies of pregnancy originate from placental dys-
function. It is essential to understand the functions of key genes in the placenta in
order to discern the etiology of placental pathologies. A paucity of animal models
that allow conditional and inducible expression of a target gene in the placenta is a
major limitation for studying placental development and function.
Results: To study the platelet-derived growth factor receptor alpha (PDGFRα)-
directed and tamoxifen-induced Cre recombinase expression in the placenta, PDGFRα-
CreER mice were crossed with mT/mG dual-fluorescent reporter mice. The expression
of endogenous membrane-localized enhanced green fluorescent protein (mEGFP) and/
or dTomato in the placenta was examined to identify PDGFRα promoter-directed Cre
expression. Pregnant PDGFRα-CreER;mT/mG mice were treated with tamoxifen at
various gestational ages. Upon tamoxifen treatment, reporter protein mEGFP was
observed in the junctional zone (JZ) and chorionic plate (CP). Furthermore, a single
dose of tamoxifen was sufficient to induce the recombination.
Conclusions: PDGFRα-CreER expression is restricted to the JZ and CP of mouse
placentas. PDGFRα-CreER mice provide a useful tool to conditionally knock out
or overexpress a target gene in these regions of the mouse placenta.
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1 | INTRODUCTION
The placenta is a transient and autonomous organ, playing an
essential role in fetal growth. The placenta provides a sole
interface for nutrient and gas exchange between the fetus and
the mother. Many other functions have been identified in pla-
centas. For example, the placenta secretes hormones into
maternal circulation, which regulate maternal metabolic and
immune adaptations to pregnancy. Abnormality in placental
development leads to pregnancy complications that affect not
only fetal development but also maternal.1,2 Therefore, eluci-
dating the underlying mechanisms of placental development
and its functions is essential for the prevention and treatment of
placenta-originated complications. Although genetic research
has substantially improved our understanding of placental
development, it is still limited by a lack of appropriate tools for
gene manipulation in the placenta.3
Through conventional transgenic and gene-targeted
approaches, systemic gene manipulation has identified the
Abbreviations: CP, chorionic plate; CreER, tamoxifen-dependent Cre
recombinase; DB, decidua basalis; E, embryonic day; Epcam, epithelial cell
adhesion molecule; IF, immunofluorescence; JZ, junctional zone; La, laby-
rinth; mEGFP, membrane-enhanced green fluorescent protein; mT,
dTomato; PDGFRα, platelet-derived growth factor receptor alpha.
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functions of myriad genes. However, global manipulation of
many genes results in embryonic lethality, precluding the
postnatal study of these genes.4 In addition, the complex inter-
action between organs makes the identification of the key
organ expressing the gene of interest challenging. Thus,
methods for conditional tissue-specific gene targeting have
been developed, among which the most widely used is the
Cre/loxP recombination.5 Cre recombinase, under the direc-
tion of a tissue-specific promoter, catalyzes a directional DNA
recombination between two loxP sites, allowing a tissue-
specific gain- or loss-of function of the targeted gene. However,
many genes are expressed in a stage-specific and tissue-specific
manner, especially during development. Therefore, to tempo-
rally manipulate target gene expression, the inducible Cre/loxP
system has been developed by adding exogenous ligand-
dependent Cre expression mechanisms. Among the inducible
Cre/loxP systems, the tamoxifen-dependent Cre recombinase
(CreER) is the most successful and widely used, in which
Cre expression construct was fused to the human estrogen
receptor ligand-binding domain.6
Using the promoter from a specific gene or a chimeric
DNA construct to direct Cre expression in specific cells is
the key component of the Cre/loxP system. Although several
promoters have been used to target transgene expression in
trophoblast lineages,7–13 to our knowledge very few studies
have been conducted using inducible Cre/loxP specifically
for placental research.14,15 Furthermore, in both of these
models, broadly expressed Cre transgenic animals were uti-
lized, complicating the interpretation of the results.
Platelet-derived growth factor receptor alpha (Pdgfrα)
gene encodes a cell surface receptor tyrosine kinase,16 which
is expressed in a tissue-specific manner.17 In mouse embryo-
genesis, Pdgfrα is expressed in primitive mesoderm and
endoderm precursors. At embryonic day (E) 6.5, the tran-
script was detected in mesenchyme precursors (somites,
branchial arches, and limb bud), as well as in visceral endo-
derm.18 It is also expressed in both premigratory and migra-
tory neural crest cell populations and is required for neural
crest migration and palatogenesis.19 Interstitial cells of kid-
ney have also been shown to express pdgfrα at E17.5 in
mouse20 and in developing human kidney.21
Pdgfrα was first reported to be expressed in the mouse pla-
centa by Ogura et al.22 They showed its expression in a primi-
tive endoderm-derived structure: the intraplacental yolk sac,
which contributed to the chorioallantoic placenta and contin-
ued to strongly express PDGFRα until prenatal stages. In addi-
tion, intraplacental yolk sac was absent from mutant embryos
not expressing pdgfrα, highlighting the primary role of this
gene for the formation of this structure.22 In addition to its
highest expression level23 and developmental role in mouse
placenta22,24; Pdgfrα may regulate trophoblast proliferation in
human placenta.25 Therefore, we hypothesized that the PDGFRα
promoter could direct Cre recombinase expression in the
placenta. We anticipated that the expression profile of the
PDGFRα-Cre construct might differ from endogenous
Pdgfrα gene described above; as in the absence of targeted
knock-in, the incorporation of a transgene into genomic DNA
is random.26 Despite having the same promoter DNA, it is pos-
sible to observe differences in expression profiles between the
endogenous gene and the gene directed by a manmade con-
struct. Therefore, we undertook a careful characterization of the
expression of Cre in the placenta of these transgenic mice.
The PDGFRα-CreER transgenic mouse was first devel-
oped to study oligodendrocyte precursor cells in the fore-
brain and spinal cord of adult mice.27 The mT/mG mice are
well characterized and commonly used as a dual-fluorescent
reporter mouse model, in which a membrane-localized red
fluorescent protein (dTomato [mT]) is constitutively
expressed prior to Cre recombinase exposure.28 Expression
of Cre recombinase permanently inactivates dTomato while
activating a membrane-localized enhanced green fluorescent
protein (mEGFP), thus allowing the identification of all Cre-
expressing cells and their daughters. We crossed PDGFRα-
CreER and mT/mG mice to verify and characterize PDGFRα
promoter-directed Cre recombinase expression and activity in
the placenta.
Our results showed that the reporter mEGFP was
expressed at E12.5 in trophoblast cells in the junctional zone
(JZ) and at E18.5 in the JZ and the chorionic plate (CP) after
tamoxifen induction. However, tamoxifen-induced recombi-
nation was also detected in fetal bones. Our study indicates
that, despite some expression in fetal cells, the PDGFRα-
CreER mice can be a useful tool to temporally manipulate
target gene(s) in the placenta.
2 | RESULTS
2.1 | Creation of the PDGFRα-CreER;
mT/mG mice
The line of PDGFRα-CreER mice was created by coupling the
mouse PDGFRα promoter-directed Cre with mutated human
estrogen receptor ligand-binding domain.29,30 The mT/mG
mice are dual-fluorescent reporter transgenic mice possessing
loxP sites on either side of a membrane-targeted mT tandem
dimer followed by a strong stop codon. Prior to the Cre-
mediated excision, almost all cells express a membrane-
targeted red fluorescence. Following Cre-mediated excision,
the mT cassette is removed along with the stop codon, all-
owing the expression of the mEGFP driven by the CAG pro-
moter (Figure 1A). We crossed PDGFRα-CreER mice with
mT/mG mice and produced transgenic mice with hemizygous
PDGFR-CreER allele and homozygous mT/mG (named as
PDGFRα-CreERTg;mT/mGfl/fl). The resulting offspring are
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viable, with no significant alteration between the control
and transgenic fetuses regarding the litter size (6.67 ± 0.33
vs 7.66 ± 0.88; P = 0.35), E18.5 placental weight
(0.149 ± 0.01 vs 0.143 ± 0.01; P = 0.50), and E18.5 fetal
weight (0.99 ± 0.04 vs 1.06 ± 0.07; P = 0.42).
2.2 | Tamoxifen-induced mEGFP expression
in the placentas of PDGFRα-CreERTg;
mT/mGfl/fl mice
PDGFRα-CreER Tg;mT/mGfl/fl male breeders were mated
with PDGFRα-CreER Tg;mT/mGfl/fl females. To assess the
ability of the CreER to induce specific recombination in the
placenta, pregnant PDGFRα-CreER Tg;mT/mGfl/fl dams
were gavaged daily with tamoxifen for five consecutive days
from E13.5 to E17.5, then placentas were collected at E18.5
(Figure 1B). mEGFP signals were observed in trophoblast cells
in the placental JZ (Figure 2A, A1), as well as from the CP
(Figure 2A,A2). In the control littermates with PDGFRα-
CreER−;mT/mGfl/fl genotype, no mEGFP signal was observed
in the placentas (Figure 2C). As expected, no mEGFP signal
was detected in placentas of PDGFRα-CreETg;mT/mGfl/fl
mice, which received vehicle treatment (Figure 2B). Interest-
ingly, no mEGFP signal was seen in the labyrinth (La) layer.
These results indicated that PDGFRα promoter-directed Cre-
recombinase is expressed in the trophoblast cells in the JZ
and CP only.
2.3 | mEGFP colocalized with Tpbpα and
Epcam
Since we detected mEGFP expression in the JZ, we assumed
that the cells targeted by the PDGFRα promoter were
spongiotrophoblast cells. To confirm this hypothesis, immu-
nofluorescence (IF) was conducted using an antibody against
trophoblast specific protein alpha (Tpbpα), a gene that is used
to identify spongiotrophoblast and glycogen trophoblast in
the JZ.13,31 As expected, Tpbpα protein was observed only in
the cells of JZ (Figure 3A). The areas of mEGFP and Tpbpα
expression in the JZ were overlapped (Figure 3A1,A2),
whereas the CP did not show Tpbpα-positive cells (Fig. 3A3).
These results confirmed that the cells tagged by PDGFRα
promoter-directed mEGFP in the JZ are spongiotrophoblast
and/or glycogen trophoblast.
FIGURE 1 Transgenic animals design and
tamoxifen treatments. A: The PDGFRα-CreER mice
were crossed with mT/mG reporter mice to produce
PDGFRα-CreER;mT/mG mice. Tamoxifen
treatment induces Cre recombinase expression, then
the dTomato transgene is deleted and allows the
expression of the mEGFP. B: Pregnant mice were
orally fed with tamoxifen (2 mg in 100 μL
sunflower oil) for five, four, three, or two
consecutive days starting at E13.5 and placentas
collected at E18.5. C: Tamoxifen was administrated
to transgenic mice at E13.5 and E14.5. Placentas
were harvested at 18.5. D: A five-day tamoxifen
treatment was administrated to pregnant mice from
E7.5 to E11.5; tissues were collected at E12.5.
CreER, tamoxifen-dependent Cre recombinase;
E, embryonic day; mEGFP, membrane-localized
enhanced green fluorescent protein; PDGFRα,
platelet-derived growth factor receptor alpha
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The CP is part of the chorioamniotic membranes con-
taining amniotic epithelial cells and mesenchymal cells.32
As a marker of epithelial cells, Epithelial cell adhesion mole-
cule (Epcam) was used to target the CP cells. Figure 3B
shows that part of the mEGFP-tagged cells overlapped with
the Epcam-positive cells in the CP (Figure 3B3), as well as
in the JZ (Figure 3B1,B2). No signal for either Epcam or
Tpbpα was seen in the negative control (Figure 3C).
2.4 | Effect of tamoxifen treatment duration
on Cre expression
Tamoxifen is an estrogen receptor modulator, and its metabo-
lites interact with the growing fetus. It has been reported that
this molecule can be teratogenic and disrupt the maternal-fetal
interface,33 leading to adverse effects on the fetus in both ani-
mals34 and humans.35 Although a five-day treatment is con-
ventionally used in inducible Cre-recombination systems, we
assessed the ability of a shorter treatment to induce the recom-
bination in order to reduce the adverse effects of tamoxifen on
pregnancy and fetus. We then decreased the treatment duration
in a stepwise manner, from five to two days (Figure 1B). Inter-
estingly, the pattern of expression of mEGFP was the same,
independent of the length of the tamoxifen treatment
(Figure 4), with a signal present in the JZ and the CP. However,
although the mEGFP signal intensity appeared similar in the
CP, we did observe a decrease in the JZ signal that was propor-
tional to shorter treatment times (Figure 4A–D).
FIGURE 2 Tamoxifen-induced Cre recombinase expression in mouse placentas. Placentas were collected at E18.5 after 5 consecutive days
tamoxifen gavaging of pregnant PDGFRα-CreER;mT/mG mice. Tissue were cryosectioned and stained with DAPI. Endogenous mEGFP signals
were observed in trophoblast cells in the JZ and the CP (A,A1,A2). Only red dTomato fluorescent protein was observed in placenta without
tamoxifen treatment (B,B1,B2) and fetuses without PDGFRα-CreER transgene (C). Scale bar = 1 mm for top panel; 20X for two bottom panels.
CP, chorionic plate; DB, decidua basalis; JZ, junctional zone; La, labyrinth; mEGFP, membrane-enhanced green fluorescent protein; CreER,
tamoxifen-dependent Cre recombinase; E, embryonic day; PDGFRα, platelet-derived growth factor receptor alpha
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FIGURE 3 Colocalization of mEGFP and Tpbpα or Epcam protein in trophoblast cells. Placentas were collected at E18.5 after five
consecutive days tamoxifen gavaging of pregnant PDGFRα-CreER;mTmG mice, and then cryosectioned and stained. A: Tpbpα IF showed a strong
signal overlapping with the mEGFP signal within the JZ (A1,A2,A3) of the placentas. B: Epcam signal is seen from the JZ as well (B1,B2), but also
overlapped part of the mEGFP-tagged cells in the CP (B3). No Tpbpα or Epcam signal is detected from the negative control (C1,C2,C3). A1,A2,A3,
B1,B3,C1,C3: 10X high-power view of insets in the upper panel. B2,C2: 20X magnification. CP, chorionic plate; CreER, tamoxifen-dependent Cre
recombinase; E, embryonic day; Epcam, epithelial cell adhesion molecule; IF, immunofluorescence; JZ, junctional zone; La, labyrinth; mEGFP,
membrane-enhanced green fluorescent protein; PDGFRα, platelet-derived growth factor receptor alpha; Tpbpα, trophoblast specific protein alpha
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2.5 | Stability of Cre expression and induction
of EGFP at mid-gestation
In the first treatment (Figure 1B), one day separated the last
dose of tamoxifen from the tissue collection date (from
E17.5 to E18.5), thereby not allowing us to estimate the effi-
ciency of the recombination. Therefore, we next assessed if
the recombination occurred temporarily or was stable within
the tissue, through a single oral dose of tamoxifen at E13.5
or doses at E13.5 and E14.5 followed by the consecutive
days without treatment until E18.5 (Figure 1C). The single-
dose treatment revealed a clear membrane-localized EGFP
signal in both the JZ (Figure 5A,A1) and the CP (Figure 5A,
A2). If the treatment was extended to a second dose the next
day (E13.5 + E14.5), the same pattern of expression was
observed (Figure 5B,B1,B2) but the mEGFP signal intensity
in JZ appeared to be increased (Figure 5B1 vs Figure 5A1).
Finally, to assess if PDGFRα-mediated Cre expression
was inducible at earlier stages of pregnancy, we per-
formed a tamoxifen treatment from E7.5 to E11.5 (Figure 1D).
Figure 5C shows that this treatment exhibited a strong
recombination, localized and restricted to the JZ of pla-
centas collected at E12.5 from PDGFRα-CreERTg;mTmGfl/fl
mice (Figure 5C,C1,C2).
2.6 | PDGFRα-directed Cre expression in fetal
tissue
PDGFRα is known to be expressed in some cells during mouse
embryogenesis.18 Its expression is particularly detected in the
sclerotome (ie, at the origin of the formation of the vertebrae)
and contributes to the development of the bones of the skull,36
as well as in tooth bud, developing lens, and choroid plexus.24
To investigate the PDGFRα promoter-directed Cre expres-
sion in fetal tissue, median sagittal sections from E18.5 fetuses
were analyzed. In PDGFRα-CreERTg;mTmGfl/fl fetuses, regard-
less of the length of tamoxifen treatment, mEGFP signal was
observed only from the eye (Figure 6A1,B1,C1,D1) and
bones (Figure 6A2,B2,C2,D2), corroborating PDGFRα gene
expression during organogenesis.24 No recombination was
detectable in fetuses from dams that received sunflower oil
vehicle treatment (Figure 6E). As in the placenta, the
mEGFP signal intensity seemed to decrease proportionally
to the duration of tamoxifen treatment (Figure 6A–D).
3 | DISCUSSION
Inducible conditional gene knockout or transgene animal model
is a powerful tool in biomedical research. Unfortunately, this
FIGURE 4 Effect of tamoxifen
treatment duration on transgene
expression. PDGFRα-CreERTg;
mTmGfl/fl placentas were collected at
E18.5 after five (A), four (B), three
(C), or two (D) consecutive days of
tamoxifen gavaging. Endogenous
mEGFP and mTomato proteins were
visualized. Left panels: mEGFP only;
right panels: mEGFP + dTomato +
DAPI. CreER, tamoxifen-dependent
Cre recombinase; E, embryonic day;
mEGFP, membrane-enhanced green
fluorescent protein; mT, dTomato;
PDGFRα, platelet-derived growth
factor receptor alpha. Scale
bar = 1 mm
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technique has not been able to be widely used in the
research of placental biology due to the lack of appropriate
transgenic models for these studies. In our efforts to estab-
lish an inducible placenta-specific gene manipulation, we
took advantage of previously created PDGFRα-CreER mice
due to high-level PDGFRα expression in the placenta.23
By crossing mT/mG reporter mice with PDGFRα-CreER
mice, our study showed that tamoxifen treatment induced
the target gene expression in the placenta. Although PDGFRα
promoter–directed Cre recombinase expression can be detected
in some fetal tissues, the PDGFRα-CreER mice provide a
useful tool to temporally manipulate target gene in tropho-
blast cells in JZ and CP for the studies that focus on placental
development.
FIGURE 5 Single tamoxifen treatment during mid-gestation induced Cre-recombinase expression in placentas. Placentas were collected at
E18.5 after a single dose of tamoxifen gavaging of pregnant PDGFRα-CreERTg;mTmGfl/fl mice at E13.5 (A) or E13.5/E14.5 (B), followed by
consecutive days with no treatment before tissue collection. Tissue were then cryosectioned and stained with DAPI. mEGFP is detected in the JZ
(A1,B1) as well as in the CP (B1,B2). C: E12.5 PDGFRα-CreERTg;mTmGfl/fl mice express the transgene in the JZ (C,C1,C2). A1,C1: 10X
magnification. A2,B1,B2: 20X magnification. CP, chorionic plate; DB, decidua basalis; CreER, tamoxifen-dependent Cre recombinase;
E, embryonic day; JZ, junctional zone; La, labyrinth; PDGFRα, platelet-derived growth factor receptor alpha. Scale bar = 1 mm
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FIGURE 6 PDGFRα-directed Cre recombinase expression in fetal tissues. PDGFRα-CreERTg;mTmGfl/fl fetuses were collected at E18.5 after
five (A), four (B), three (C), or two (D) consecutive days of tamoxifen gavaging. Fetuses express mEGFP signal in craniofacial bones (A1,B1,C1,D1)
and vertebrae (A2,B2,C2,D2). E: Absence of GFP expression in fetal tissue whether tamoxifen is not administrated, either in craniofacial bones (E1) or
vertebrae (E2). The dTomato signal was removed intentionally to give a better visualization of the leaking mEGFP signal in fetal tissues (A,B,C,D) or
the absence of mEGFP signal in the negative control (E). Scale bar, left panel = 2 mm. Craniofacial bones, vertebrae images: 4X magnification of
insets in the left panel. CreER, tamoxifen-dependent Cre recombinase; E, embryonic day; mEGFP, membrane-localized enhanced green fluorescent
protein; PDGFRα, platelet-derived growth factor receptor alpha
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Genetic manipulation has been widely used to study target
gene's function under both physiological and pathological con-
ditions. Temporal and tissue-specific transgene and gene dele-
tion are especially important for research in dynamically
developing organs and tissues. Unfortunately, the inducible
Cre/LoxP recombination systems have not been used in placenta
study due to a paucity of trophoblast-specific promoter-directed
Cre transgenic tools. Alternatively, two other strategies have
been developed for manipulating genes in the placenta: 1) cell-
based modulation of placental gene expression by intraplacental
engraftment37 or chimerism,38 in which genetically modified
cells are introduced into a placenta; and 2) viral vector-mediated
gene delivery using recombinant adenoviruses,39 retroviruses,40
or lentiviruses41,42 for genetic modulation. However, these alter-
native approaches still cannot temporally control target gene
expression. In addition, the requirement of sophisticated system
and skills of these alternative approaches prevents their usage in
an ordinary laboratory setting.
PDGFRα is highly expressed in the placenta.22 Our results
showed that PDGFRα promoter directed Cre recombinase spe-
cifically in the trophoblast cells in JZ and CP. This finding was
confirmed by the colocation (or overlap) of mEGFP reporter
with Tpbpα, which is expressed in both spongiotrophoblast
and glycogen trophoblast in the JZ.13,31 More recently, La tro-
phoblast progenitor cells, which are proliferative around mid-
gestation and differentiate into syncytiotrophoblast and sinusoi-
dal trophoblast giant cells, have been identified in the CP.43
These cells support the development and growth of the La and
express the cell adhesion protein Epcam.43 Given the pattern of
mEGFP expression that we observed, and the fact that it was
expressed in the region of the placenta where La trophoblast
progenitors have been described, we examined co-expression
with Epcam to determine if mEGFP was expressed in these
cells. Our results showed that Epcam overlapped with
PDGFRα-Cre activity in the CP. However, we did not observe
mEGFP expression in trophoblast cells of the La following
activation of Cre activity at any time beginning at E13.5. This
result suggested that Epcam/mEGFP dual-positive cells in the
CP were not likely to be trophoblast progenitor cells. This con-
clusion was supported by the results of our experiments, in
which PDGFRα-Cre was activated between E7.5 and E11.5
and mEGFP was absent from the La at E12.5, clearly ruling
out the possibility that PDGFRα-Cre was active in Epcam-
positive trophoblast progenitors. Surprisingly, PDGFRα-Cre
activity was also absent from the CP at E12.5. We conclude,
therefore, that in addition to the JZ, PDGFRα expression in the
CP is primarily in the intraplacental yolk sac beginning at
E13.5. In addition to expression in the intraplacental yolk sac,
we also observed Epcam in the JZ at E18.5, which, to our
knowledge, has not previously been reported.
Since mEGFP signal was not detected in the La layer,
our results indicate that PDGFRα-directed Cre is unable to
induce recombination in the trophoblast cells of this layer.
Therefore, PDGFRα-CreER mice are not suitable to express
Cre and manipulate target gene in La cells (ie, syncy-
tiotrophoblasts and sinusoidal trophoblast giant cells). On
the other hand, this model is of great benefit to studies
focusing cells within the JZ and CP, which have previously
relied on the use of Tpbpα-Cre, the expression of which can-
not be temporally controlled.13
Although PDGFRα-directed Cre expression is abundant
in the placenta, the recombination also occurred in the fetus,
such as in craniofacial bones, vibrissae, and vertebrae
(Figure 6). Therefore, caution should be taken for any study
with an aim beyond placental development when using
PDGFRα-CreER mice.
Tamoxifen is known for adverse effects on placental/fetal
development. Our model is not exempt from potential side
effects. Therefore, tamoxifen treatment for control mice is rec-
ommended by doing littermates comparison using hemizygous
PDGFRα-CreER breeders. However, these side effects are not
dependent on Cre expression and are a general shortfall of all
models using tamoxifen to induce gene expression during
pregnancy. Whereas not assessed specifically in our study, we
did not observe any defects in placentation between tamoxifen-
treated and untreated pregnant mice; furthermore, we did not
find any changes in placenta size, litter size, placenta weight,
or fetal weight (see results, section 2.1 for values).
In summary, using the PDGFRα-CreERTg;mTmGfl/fl trans-
genic mice, our study demonstrated that Cre recombinase can
be expressed in the trophoblast cells in JZ and CP under control
of PDGFRα promoter and tamoxifen induction. Although a sin-
gle tamoxifen treatment induced recombination in the placentas,
demonstrating the high efficiency of this model, the longer the
treatment, the stronger the signal (whether at E13.5-E17.5 [Fig-
ures 1B and 4] or at E13.5-E14.5 [Figures 1C and 5]). How-
ever, expression of Cre in fetal bone and other tissues must also
be considered when interpreting the effect of placenta gene
manipulation on fetal development. Together, our study indi-
cates that PDGFRα-CreER mice will be a valuable tool to tem-
porally knock out or overexpress a target gene in the placenta
and to study that gene's function in placental development.
4 | EXPERIMENTAL PROCEDURES
4.1 | Material
Tamoxifen was purchased from Sigma (#T5648, St Louis,
MO). Rabbit anti-Tpbpα (#ab104401) and rabbit anti-Epcam
(#ab71916) were both obtained from Abcam (Cambridge,
MA). The goat anti-rabbit Alexa Fluor 647 secondary anti-
body (#A21244) was purchased from Thermo Fisher Scien-
tific. The ProLong Gold mounting medium (#P36935) was
from Invitrogen (Carlsbad, CA). mT/mG and Cre primers
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and Reverse transcription polymerase chain reaction (RT-
PCR) probes were purchased from Integrated DNA Technol-
ogies (Coralville, IA).
4.2 | Experimental animals
B6N.Cg-Tg(pdgfrα-cre/ERT)467Dbe/J mice (Jackson stock
#018280) were cross-mated with B6.129(Cg)-Gt(ROSA)
26Sortm4(ACTB-tdTomato,-EGFP)Luo/J mice (Jackson stock
#007676) reporter mice in order to generate PDGFRα-
CreER;mT/mG mice (Figure 1 A). Pregnancy was identified
by the presence of a vaginal plug and was designated E0.5.
Placentas and fetuses were collected via Caesarian section at
E12.5 or E18.5. Animals were housed at 24C with a
12-hour light-dark cycle (6 AM/6 PM) with food and water
provided ad libitum. Tail biopsies of mice were used to
extract genomic DNA. Genotypes were determined by
using regular PCR for Cre transgene or real-time PCR
protocols for mT/mG transgenes.24 All experiments were
performed in accordance with the Guide for the Care
and Use of Laboratory Animals published by the United
States National Institutes of Health and carried out under
the Association for Assessment and Accreditation of
Laboratory Animal Care guidelines with approval from
the University of California San Diego Animal Care and
Use Committee.
4.3 | Tamoxifen induction of transgene
expression
To induce expression of the Cre recombinase, pregnant
PDGFRα-CreER;mT/mG female mice were gavaged using a
feeding cannula with 2 mg of tamoxifen (20 mg/mL in
100 μL sunflower oil per day). There were three treatments.
The duration of the tamoxifen treatment was detailed in the
Results section and figure legends. Briefly, treatment 1: daily
gavaging for five, four, three, or two consecutive days and
samples collected at E18.5 (Figure 1B). Treatment 2: gavaging
tamoxifen for one or two consecutive days started at E13.5,
then waited for four days and collected tissue at E18.5
(Figure 1C). Treatment 3: daily gavaging for five consecutive
days from E7.5 to E11.5, then collected tissue at E12.5
(Figure 1D). Prior to tissue collection, mice were anesthetized
with intraperitoneal injection of ketamine/xylazine and per-
fused intracardially with phosphate buffered saline (PBS).
4.4 | Histology and immunofluorescence
Mouse placenta biopsy were fixed with 4% (vol./vol.) para-
formaldehyde in PBS, cryopreserved in 10% sucrose, then
30%, and embedded in OCT compound (Tissue-Tek). After
cryosectioning samples, 4-μm-thick midsagittal frozen sec-
tions were rinsed in PBS for 10 minutes and slides were
mounted in ProLong Gold containing DAPI and visualized
by fluorescent optical microscopy (Nikon, Eclipse E800).
For IF, cryosections were permeabilized in 0.1% phosphate
buffered saline with Tween 20 (PBST) for five minutes and
overlaid with 1% sodium dodecyl sulfate for five minutes to
induce antigen retrieval. They were further blocked with 2%
(vol./vol.) normal goat serum with 1% (wt./vol.) bovine
serum albumin in PBS for two hours in a humid chamber at
room temperature. Sections were then incubated with anti-
rabbit Tpbpα (1/500) or anti-rabbit Epcam (1/100) primary
antibody diluted in 2% goat serum/PBS or goat serum only
(negative control) overnight at 4C. After rinsing the slides
three times for five minutes each in PBST, samples were
overlaid with goat anti-rabbit Alexa Fluor 647 secondary
antibody (1/500 and 1/200 for Tpbpα and Epcam, respec-
tively) for two hours at RT. After washing, sections were
mounted in ProLong Gold/DAPI and visualized by fluores-
cent optical microscopy (Nikon, Eclipse E800).
4.5 | Statistical analyses
Data are expressed as a mean ± SE of the mean (SEM). Sta-
tistical analyses were performed using the Student t-test. Dif-
ferences were considered significant at P < 0.05.
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